Arun A Azad (A Azad, Arun Azad)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 24

Top Topics

Benign Prostatic Hyperplasia

Positron Emission Tomography

Chronic Myeloid Leukemia

Top Venues

BJU international

Nature communications

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Louise Kostos, Ben Tran, Arun A Azad
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Drugs (2024)
Louise Kostos, Ben Tran, Arun A Azad
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Drugs (2024)
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G Healy, Nicola Di Santo, A Douglas Laird, Fabian Zohren, Archana M Agarwal
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature medicine (2024)
Shikai Fang, Shandian Zhe, Hui Ming Lin, Arun A Azad, Heidi Fettke, Edmond M Kwan, Lisa Horvath, Blossom Mak, Tiantian Zheng, Pan Du, Shidong Jia, Robert M Kirby, Manish Kohli
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer. JCO clinical cancer informatics 7 (2023)
Archana M Agarwal, Fred Saad, Arun A Azad, Joaquin Mateo, Nobuaki Matsubara, Neal D Shore, Jayeta Chakrabarti, Hsiang-Chun Chen, Silvana Lanzalone, Alexander Niyazov, Karim Fizazi
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future oncology (London, England) (2023)
Tahlia Scheinberg, Hui Ming Lin, Michael Fitzpatrick, Arun A Azad, Paul Bonnitcha, Amy Davies, Gillian Ziona Heller, Kevin Huynh, Blossom Mak, Kate Mahon, David Sullivan, Peter J Meikle, Lisa G Horvath
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer. Prostate cancer and prostatic diseases (2023)
Kenneth Chen, Xuan Rui Sean Ong, Vasundhara Kandarpa, Chow Kit Mun, Isabella S C Williams, Ravindran Kanesvaran, John Yuen Shyi Peng, Arun A Azad, Nathan L Lawrentschuk
Is Genetic testing coming of age in advanced prostate cancer? BJU international (2023)
Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, Andre P Fay, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G Healy, Nicola Di Santo, A Douglas Laird, Fabian Zohren, Archana M Agarwal
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature medicine (2023)
L H Porter, Joe Jiang Zhu, N L Lister, S G Harrison, S Keerthikumar, D L Goode, R Quezada Urban, D J Byrne, Arun A Azad, I Vela, M S Hofman, Paul Joseph Neeson, Phillip K Darcy, J A Trapani, Renea A Taylor, Gail P Risbridger
Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nature communications 14 (1) (2023)
Andrew J Armstrong, Arun A Azad, Taro Iguchi, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D Shore, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P Haas, Arnulf Stenzl
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (15) (2022)
Mahasha P J Perera, Patrick B Thomas, Gail P Risbridger, Renea Taylor, Arun A Azad, Michael S Hofman, Elizabeth D Williams, Ian Vela
Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers 14 (3) (2022)
Martin H Voss, Arun A Azad, Aaron Richard Hansen, Jhanelle E Gray, Sarah J Welsh, Xuyang Song, Michael Kuziora, Lina Meinecke, Jorge M Blando, Ikbel Achour, Yi Wang, Farzana L Walcott, Sjoukje F Oosting
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (14) (2022)
Kim N Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J Carl Barrett, Carrie A Adelman, Ping Qiu, Ashley D Easter, Simon Dearden, Geoffrey R Oxnard, Archana M Agarwal, Arun A Azad, Johann S de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A Harrington
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Archana M Agarwal, Arun A Azad, Neal D Shore, Joan Carles, Andre P Fay, Curtis Dunshee, Lawrence Ivan Karsh, Maria Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future oncology (London, England) 18 (4) (2022)
Richard Kelly, Andrew Jensen, Nathasha Karunaratna, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Phillip Parente, Arun A Azad, Anthony Uccellini, Javier Torres, Francis Parnis, Jeffrey Goh, Edmond M Kwan, Stephen Brown, Christopher Steer, Mark Warren, Peter Gibbs, Ben Tran, Angelyn Anton
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer. BJU international (2022)
Kenneth Chen, Louise Kostos, Arun A Azad
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer. World journal of urology (2022)
Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, David A Pattison, Roslyn J Francis, Scott Williams, Shahneen Sandhu, Ian D Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G Murphy, Michael S Hofman, Arun A Azad
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU international 128 (3) (2021)
Richard Kelly, Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun A Azad, Edmond Michael Kwan, Lavinia Spain, Arun Muthusamy, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Anthony Joshua, David Pook, Olivia Baenziger, Peter Gibbs, Ben Tran
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer. BJU international (2021)
Louise Emmett, Shalini Subramaniam, Anthony M Joshua, Megan Crumbaker, Andrew Martin, Alison Y Zhang, Nisha Rana, Ailsa Langford, Jenna Mitchell, Sonia Yip, Roslyn Francis, Michael S Hofman, Shahneen Sandhu, Arun A Azad, Craig Gedye, Margaret McJannett, Martin R Stockler, Ian D Davis, null null
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU international 128 (5) (2021)
Arun A Azad, Ben Tran, Ian D Davis, Phillip Parente, Melanie Evans, Shirley Wong, Stephen Brown, Sue Evans, Jeremy Millar, Declan G Murphy, Nathan Papa
Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Internal medicine journal (2021)
Edmond M Kwan, Chao Dai, Heidi Fettke, Christine Hauser, Maria M Docanto, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K Graham, Kate Mahon, Winston Tan, Xiaohong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Jianjun Yu, Pan Du, Lisa G Horvath, Shidong Jia, Manish Kohli, Arun A Azad
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology 5 (2021)
Gail P Risbridger, Ashlee K Clark, Laura H Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L Lister, David Pook, Carmel J Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B Madsen, Hong Wang, Michelle G Richards, Birunthi Niranjan, Samantha O'Dea, Linda Teng, William Wheelahan, Zhuoer Li, Nicholas Choo, John F Ouyang, Heather Thorne, Lisa Devereux, Rodney John Hicks, Shomik Sengupta, Laurence Harewood, Mahesh Iddawala, Arun A Azad, Jeremy Goad, Jeremy Grummet, John Kourambas, Edmond M Kwan, Daniel Moon, Declan G Murphy, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Luc Furic, David L Goode, Mark Frydenberg, Mitchell G Lawrence, Renea A Taylor
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature communications 12 (1) (2021)
Angelyn Anton, Sruti Pillai, Marie Christine Semira, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun A Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Olivia Baenziger, Peter Gibbs, Ben Tran
Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJUI compass 3 (3) (2021)
Amy Davies, Marcus Foo, Chun Loo Gan, John Kourambas, Nicholas Redgrave, Scott Donnellan, Sree Appu, Scott Williams, Andrew Coleman, Eva Segelov, Jason Bradley, Geoffrey Soo, Shakher Ramdave, Edmond M Kwan, Arun A Azad
68 Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. Asia-Pacific journal of clinical oncology (2021)